Journal
CANCERS
Volume 14, Issue 15, Pages -Publisher
MDPI
DOI: 10.3390/cancers14153716
Keywords
peripheral T-cell lymphoma (PTCL); TCR signaling pathway; mutation; fusion protein
Categories
Funding
- Norman and Melinda Payson in Hematologic Cancers
- NCI [1P01CA229100-01, 1P01CA233412-01A1]
- Toni Stephenson Lymphoma Center
Ask authors/readers for more resources
Next-generation sequencing (NGS) has greatly advanced genomic studies on peripheral T-cell lymphoma (PTCL), revealing recurrent mutations and fusions in genes related to the TCR signaling pathway. This review summarizes the genetic alterations affecting TCR signaling in different subgroups of PTCL and discusses potential therapeutic agents targeting these mutations.
Simple Summary The advent of next-generation sequencing (NGS) has allowed rapid advances in genomic studies on the pathogenesis and biology of peripheral T-cell lymphoma (PTCL). Recurrent mutations and fusions in genes related to the proximal TCR signaling pathway have been identified and show an important pathogenic role in PTCL. In this review, we summarize the genomic alterations in TCR signaling identified in different subgroups of PTCL patients and the functional impact of these alterations on TCR signaling and downstream pathways. We also discuss novel agents that could target TCR-related mutations and may hold promise for improving the treatment of PTCL. Peripheral T-cell lymphoma (PTCL) comprises a heterogeneous group of mature T-cell malignancies. Recurrent activating mutations and fusions in genes related to the proximal TCR signaling pathway have been identified in preclinical and clinical studies. This review summarizes the genetic alterations affecting proximal TCR signaling identified from different subgroups of PTCL and the functional impact on TCR signaling and downstream pathways. These genetic abnormalities include mostly missense mutations, occasional indels, and gene fusions involving CD28, CARD11, the GTPase RHOA, the guanine nucleotide exchange factor VAV1, and kinases including FYN, ITK, PLCG1, PKCB, and PI3K subunits. Most of these aberrations are activating mutations that can potentially be targeted by inhibitors, some of which are being tested in clinical trials that are briefly outlined in this review. Finally, we focus on the molecular pathology of recently identified subgroups of PTCL-NOS and highlight the unique genetic profiles associated with PTCL-GATA3.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available